Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Fase 2-platformsundersøgelse af nye immunterapikombinationer som førstelinjebehandling hos deltagere med PD-L1 positiv tilbagevendende/metastatisk planocellulært karcinom i hoved og nakke

23. september 2026 opdateret af: GlaxoSmithKline

Et fase 2, randomiseret, åbent, platformsstudie ved hjælp af en masterprotokol til evaluering af nye immunterapikombinationer som førstelinjebehandling hos deltagere med recidiverende/metastaserende PD-L1 positivt planocellulært karcinom i hoved og nakke

The primary purpose of the study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC).

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

316

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Buenos Aires, Argentina, C1426ABP
        • GSK Investigational Site
      • Capital Federal, Argentina, C1181ACH
        • GSK Investigational Site
      • Ciudad Autonoma de Bueno, Argentina, C1056ABI
        • GSK Investigational Site
      • Córdoba, Argentina, 5000
        • GSK Investigational Site
      • Florida, Argentina, B1602DQD
        • GSK Investigational Site
      • Mendoza, Argentina, M5500AYB
        • GSK Investigational Site
      • San Juan, Argentina, 5400
        • GSK Investigational Site
      • Santa Fe, Argentina, 3000
        • GSK Investigational Site
      • Santo André, Brasilien, 09060-650
        • GSK Investigational Site
      • São Paulo, Brasilien, 01246-000
        • GSK Investigational Site
      • São Paulo, Brasilien, 01221-020
        • GSK Investigational Site
    • Alberta
      • Calgary, Alberta, Canada, T2N 5G2
        • GSK Investigational Site
      • Edmonton, Alberta, Canada, T6G 1Z2
        • GSK Investigational Site
    • Ontario
      • Toronto, Ontario, Canada, M4N 3M5
        • GSK Investigational Site
      • Toronto, Ontario, Canada, M5G 2M9
        • GSK Investigational Site
    • Quebec
      • Montreal, Quebec, Canada, H3T 1E2
        • GSK Investigational Site
      • Herlev, Danmark
        • GSK Investigational Site
      • Turku, Finland, 20520
        • GSK Investigational Site
    • Connecticut
      • New Haven, Connecticut, Forenede Stater, 06511
        • GSK Investigational Site
    • Iowa
      • Iowa City, Iowa, Forenede Stater, 52242
        • GSK Investigational Site
    • Missouri
      • St Louis, Missouri, Forenede Stater, 63110-1010
        • GSK Investigational Site
    • Ohio
      • Columbus, Ohio, Forenede Stater, 43210
        • GSK Investigational Site
    • Wisconsin
      • Milwaukee, Wisconsin, Forenede Stater, 53226
        • GSK Investigational Site
      • Bordeaux, Frankrig, 33075
        • GSK Investigational Site
      • Caen, Frankrig, 14075
        • GSK Investigational Site
      • Marseille, Frankrig, 13005
        • GSK Investigational Site
      • Paris, Frankrig, 75005
        • GSK Investigational Site
      • Rouen, Frankrig, 76038
        • GSK Investigational Site
      • Villejuif, Frankrig, 94805
        • GSK Investigational Site
      • Haidari - Athens, Grækenland, 12462
        • GSK Investigational Site
      • Marousi, Grækenland
        • GSK Investigational Site
    • Central Macedonia
      • Panórama, Central Macedonia, Grækenland, 552 36
        • GSK Investigational Site
      • Bari, Italien, 70124
        • GSK Investigational Site
      • Bologna, Italien, 40139
        • GSK Investigational Site
      • Florence, Italien, 50134
        • GSK Investigational Site
      • Genova, Italien, 16132
        • GSK Investigational Site
      • Milan, Italien, 20133
        • GSK Investigational Site
      • Naples, Italien, 80131
        • GSK Investigational Site
      • Novara, Italien, 28100
        • GSK Investigational Site
      • Padova, Italien, 35128
        • GSK Investigational Site
      • Roma, Italien, 00168
        • GSK Investigational Site
      • Roma, Italien, 00144
        • GSK Investigational Site
    • MI
      • Rozzano, MI, Italien, 20089
        • GSK Investigational Site
      • Aichi, Japan, 464-8681
        • GSK Investigational Site
      • Chiba, Japan, 277-8577
        • GSK Investigational Site
      • Hyōgo, Japan, 650-0017
        • GSK Investigational Site
      • Osaka, Japan, 541-8567
        • GSK Investigational Site
      • Saitama, Japan, 350-1298
        • GSK Investigational Site
      • Shizuoka, Japan, 411-8777
        • GSK Investigational Site
      • Tokyo, Japan, 104-0045
        • GSK Investigational Site
      • Oslo, Norge, 0379
        • GSK Investigational Site
      • Bielsko-Biala, Polen, 43-300
        • GSK Investigational Site
      • Katowice, Polen, 40-514
        • GSK Investigational Site
      • Krakow, Polen, 31-826
        • GSK Investigational Site
      • Przemyśl, Polen, 37-700
        • GSK Investigational Site
      • Siedlce, Polen, 08-110
        • GSK Investigational Site
      • Warsaw, Polen, 04-141
        • GSK Investigational Site
      • Almada, Portugal, 2801-951
        • GSK Investigational Site
      • Lisbon, Portugal, 1649-035
        • GSK Investigational Site
      • Porto, Portugal, 4099-001
        • GSK Investigational Site
      • Porto, Portugal, 4200-072
        • GSK Investigational Site
      • Brasov, Rumænien, 500283
        • GSK Investigational Site
      • Bucharest, Rumænien, 020142
        • GSK Investigational Site
      • Bucharest, Rumænien, 022328
        • GSK Investigational Site
      • Bucharest, Rumænien, 030171
        • GSK Investigational Site
      • Bucharest, Rumænien, 30463
        • GSK Investigational Site
      • Craiova, Rumænien, 200542
        • GSK Investigational Site
      • Floreşti, Rumænien, 407280
        • GSK Investigational Site
      • Iași, Rumænien, 700483
        • GSK Investigational Site
      • Oradea, Rumænien, 410469
        • GSK Investigational Site
      • Piteşti, Rumænien, 110283
        • GSK Investigational Site
      • Suceava, Rumænien, 720214
        • GSK Investigational Site
      • Barcelona, Spanien, 08035
        • GSK Investigational Site
      • Barcelona, Spanien, 08907
        • GSK Investigational Site
      • Barcelona, Spanien, 08023
        • GSK Investigational Site
      • Jaén, Spanien, 23007
        • GSK Investigational Site
      • Madrid, Spanien, 28041
        • GSK Investigational Site
      • Madrid, Spanien, 28040
        • GSK Investigational Site
      • Madrid, Spanien, 28034
        • GSK Investigational Site
      • Madrid, Spanien, 28010
        • GSK Investigational Site
      • Pozuelo de AlarcOn Madr, Spanien, 28223
        • GSK Investigational Site
      • Salamanca, Spanien, 37007
        • GSK Investigational Site
      • Santander, Spanien, 39008
        • GSK Investigational Site
      • Valencia, Spanien, 46009
        • GSK Investigational Site
      • Zaragoza, Spanien, 50009
        • GSK Investigational Site
      • Daegu, Sydkorea, 42601
        • GSK Investigational Site
      • Seongnam-si Gyeonggi-do, Sydkorea, 13620
        • GSK Investigational Site
      • Seoul, Sydkorea, 138-736
        • GSK Investigational Site
      • Seoul, Sydkorea, 03722
        • GSK Investigational Site
      • Suwon Kyunggi-do, Sydkorea, 443-721
        • GSK Investigational Site
      • Changhua, Taiwan, 500
        • GSK Investigational Site
      • Tainan, Taiwan, 704
        • GSK Investigational Site
      • Taipei, Taiwan, 11217
        • GSK Investigational Site
      • Taipei, Taiwan, 10002
        • GSK Investigational Site
      • Ankara, Tyrkiet (Türkiye), 06100
        • GSK Investigational Site
      • Istanbul, Tyrkiet (Türkiye), 34662
        • GSK Investigational Site
      • Izmir, Tyrkiet (Türkiye), 35040
        • GSK Investigational Site
      • Aachen, Tyskland, 52074
        • GSK Investigational Site
      • Berlin, Tyskland, 12203
        • GSK Investigational Site
      • Giessen, Tyskland, 35392
        • GSK Investigational Site
      • Hamburg, Tyskland, 20246
        • GSK Investigational Site
      • Regensburg, Tyskland, 93053
        • GSK Investigational Site
      • Ulm, Tyskland, 89075
        • GSK Investigational Site
    • Hesse
      • Frankfurt am Main, Hesse, Tyskland, 60488
        • GSK Investigational Site
    • North Rhine-Westphalia
      • Essen, North Rhine-Westphalia, Tyskland, 45122
        • GSK Investigational Site
      • Győr, Ungarn, 9024
        • GSK Investigational Site
      • Kecskemét, Ungarn, 6000
        • GSK Investigational Site
      • Pécs, Ungarn, 7624
        • GSK Investigational Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Have histologically or cytologically-confirmed HNSCC that is R/M and is considered incurable by local therapies. A) Subjects must not have had prior systemic therapy administered in the R/M setting. Chemoradiation therapy which was completed more than 4 months prior to signing consent if given as part of multimodal treatment for locally advanced disease is allowed B) The eligible primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx C) Subjects may not have a primary tumor site of nasopharynx (any histology)
  • Has measurable (target) disease based on RECIST 1.1 as determined by the investigator.
  • Has an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
  • Provides a tumor tissue sample obtained at the time of or after the initial diagnosis of R/M HNSCC. A fresh tumor tissue sample obtained within 90 days of screening is highly preferred, If fresh biopsy is not possible, an archival tumor specimen is acceptable unless it was obtained prior to administration of chemoradiation for the treatment of a participant's tumor. Needle or excisional biopsies or resected tissue is required. Cytological specimens such as fine needle aspirates, bone marrow samples, or cell blocks are not acceptable. Bone specimen is not acceptable.
  • Has tumor Programmed death ligand 1 (PD-L1) expression
  • If the primary tumor site is oropharyngeal carcinoma, the participant must have Human papillomavirus (HPV) results

Exclusion Criteria:

  • Has received prior therapy with any immune checkpoint inhibitors, including antibodies or drugs targeting Programmed death protein 1 (PD-1), PD-L1, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine based inhibitory motif domains (TIGIT), Cluster of differentiation (CD) 96, or other immune checkpoint pathways.
  • Participants with previous malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, esophageal, colon, endometrial, cervical/dysplasia, melanoma, or breast) unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period.
  • Have active tumor bleeding or a high risk of bleeding (examples include but are not limited to radiographic evidence of major blood vessel invasion/infiltration or tumor demonstrates >90 degree abutment or encasement of a major vessel [carotid, jugular, bronchial artery] and/or exhibits other high-risk features such as arteriovenous fistula).
  • Has PD within 4 months of completion of curatively intended treatment for locoregionally advanced HNSCC
  • Participants with any carcinomatous meningitis or leptomeningeal spread and those with uncontrolled or symptomatic Central Nervous System (CNS) metastases
  • Active autoimmune disease that has required systemic disease-modifying or immunosuppressive treatment within the last 2 years. (Stable, medically managed autoimmune endocrinopathies are acceptable if participant otherwise meets entry criteria.)

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Dostarlimab monoterapi

Dostarlimab will be administered.

Eksperimentel: Delstudie 1: Dostarlimab og Belrestotug

Dostarlimab will be administered.

Belrestotug will be administered.

Eksperimentel: Delstudie 2: Dostarlimab og nelistotug

Dostarlimab will be administered.

Nelistotug will be administered.

Eksperimentel: Delstudie 3: Dosarlimab og Belrestotug og nelistotug

Dostarlimab will be administered.

Belrestotug will be administered.

Nelistotug will be administered.

Eksperimentel: Subundersøgelse 4: Dostarlimab og Remzistotug

Dostarlimab will be administered.

Remzistotug will be administered.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Confirmed Objective Response Rate (ORR) compared between Sub studies and Dostarlimab monotherapy
Tidsramme: Up to approximately 24 months

Confirmed ORR is defined as the percentage of participants achieving confirmed Complete Response (CR) or Partial Response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator assessment.

Up to approximately 24 months

Sekundære resultatmål

Resultatmål
Tidsramme
Antal deltagere med TEAE'er, der fører til dosisændringer eller afbrydelse af undersøgelsesintervention
Tidsramme: Op til cirka 24 måneder
Op til cirka 24 måneder
Antal deltagere med klinisk signifikante fund i vitale tegn, elektrokardiogram (EKG) og laboratorietestparametre
Tidsramme: Op til cirka 24 måneder
Op til cirka 24 måneder
Antal deltagere med akutte behandlingshændelser (AE'er), behandlingsfremkomne alvorlige bivirkninger (SAE) og behandlingsfremkomne bivirkninger af særlig interesse (AESI)
Tidsramme: Op til cirka 24 måneder
Op til cirka 24 måneder

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Studieleder: GSK Clinical Trials, GlaxoSmithKline

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

14. november 2023

Primær færdiggørelse (Faktiske)

10. september 2026

Studieafslutning (Anslået)

31. december 2027

Datoer for studieregistrering

Først indsendt

21. september 2023

Først indsendt, der opfyldte QC-kriterier

29. september 2023

Først opslået (Faktiske)

2. oktober 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

24. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

23. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 219885
  • 2023-503428-24 (Registry Identifier: CTIS)
  • 2023 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

IPD-delingstidsramme

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

IPD-delingsadgangskriterier

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner